Zobrazeno 1 - 10
of 231
pro vyhledávání: '"Gary, Freed"'
Autor:
Harriet Hiscock, Melissa Mulraney, Daryl Efron, Gary Freed, David Coghill, Emma Sciberras, Hayley Warren, Michael Sawyer
Publikováno v:
Australian Journal of Psychology, Vol 72, Iss 1, Pp 31-40 (2020)
Objective Retrospective, parent‐reported data suggest that 50% of Australian children with mental health disorders miss out on care. In a national sample, we aimed to determine the proportion receiving mental health services and associated characte
Externí odkaz:
https://doaj.org/article/cf2d3bc33a5b4579a50f283102f1df2c
Autor:
PR Newswire
Publikováno v:
PR Newswire US. 11/21/2022.
Publikováno v:
Journal of Paediatrics and Child Health. 59:487-492
Autor:
Malcolm, Risk, Salim S, Hayek, Elena, Schiopu, Liyang, Yuan, Chen, Shen, Xu, Shi, Gary, Freed, Lili, Zhao
Publikováno v:
The Lancet Rheumatology. 4:e775-e784
There is a scarcity of research regarding the effectiveness of the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking immunosuppressant medications, and no data are published to date pertaining to their effectiven
Autor:
Harriet Hiscock, Rachel O'Loughlin, Cath Laird, Rachel Pelly, Jessica Holsman, Martin Wright, Ed Oakley, Gary Freed
Publikováno v:
International Journal of Integrated Care, Vol 19, Iss 4 (2019)
Introduction: Over the past two decades, Australia’s child population has grown by 12%, yet fewer children are seen by General Practitioners (GP) (Freed, 2011) and more present to emergency departments (Freed, 2015) and hospital outpatient clinics
Externí odkaz:
https://doaj.org/article/84f1443371664afcb9d275a1bec4e956
Publikováno v:
The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 72(1)
The BNT162b2 (Pfizer-BioNTech) is approved for adolescents aged 12-17 years. We estimated BNT162b2 vaccine effectiveness (VE) and a booster dose effectiveness in adolescents aged 12-17 years and the impact of opening schools and the Omicron variant o
Autor:
Chen Shen, Malcolm Risk, Elena Schiopu, Salim S Hayek, Tiankai Xie, Lynn Holevinski, Cem Akin, Gary Freed, Lili Zhao
Publikováno v:
Ann Rheum Dis
ObjectivesWe intended to assess the effectiveness of all three US Food and Drug Administration approved COVID-19 vaccines at preventing SARS-CoV-2 infection and COVID-19 hospitalisation in a large cohort of individuals on immunosuppressants for a div
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471b8b4d97e64bf6d4d495b1ebf87c94
https://europepmc.org/articles/PMC9422955/
https://europepmc.org/articles/PMC9422955/
Autor:
Malcolm Risk, Chen Shen, Salim S Hayek, Lynn Holevinski, Elena Schiopu, Gary Freed, Cem Akin, Lili Zhao
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(1)
Background There is a lack of data regarding how the Delta variant of coronavirus disease 2019 (COVID-19) has impacted the effectiveness of the BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Johnson & Johnson–Janssen) vaccines
Publikováno v:
Critical Care Medicine. 49:19-19
Publikováno v:
Journal of paediatrics and child health. 54(6)